Marijuana and Mental Health: What a Major Review Reveals
The cannabis mental health efficacy review reveals insufficient evidence supporting cannabis as an effective treatment for anxiety, depression, and PTSD. This major review highlights the lack of clinical benefit for these mental health conditions.…
‘No evidence’ cannabis works for most mental health disorders: Review – RACGP
This review highlights cannabis mental health conditions treatment lacks sufficient evidence for efficacy. Despite widespread use, most psychiatric disorders show no proven benefit. Clinicians must counsel patients on risks and evidence gaps.
The Endocannabinoid System, Immunomodulation, and LPS-Induced Inflammation
Understanding endocannabinoid system immunomodulation is critical for clinicians managing inflammatory conditions. This system regulates immune responses and inflammation triggered by lipopolysaccharide exposure. Insights into this mechanism inform…
Endocannabinoid System Clinical Research: 2024 RCT Review
This 2024 RCT review highlights digital mental health intervention cannabis research focusing on the Minder mobile app. The study evaluates its impact on university students' mental health and substance use. Digital tools like this are promising for…
Endocannabinoid System Clinical Research: CBD & Metabolism Analysis
This cannabidiol glucose tolerance clinical research evaluates the impact of low-dose CBD supplementation on metabolic health. The study found no significant improvements in glucose tolerance or gut microbiome composition. These findings highlight the…
Cannabinoid Pharmacology Clinical Funding Insights 2026
This article reviews cannabinoid pharmacology clinical funding and its impact on cannabis medicine. It highlights policy trends in psychedelic therapy funding for low-income populations. The discussion addresses legal disparities affecting cannabis…
SC Republicans Divided on Intoxicating Hemp Ban: Regulatory Challenges
Intoxicating hemp products regulation in South Carolina is currently divided among lawmakers, creating uncertainty for clinicians and patients. This regulatory gap affects how healthcare providers counsel patients on THC product use and safety.…
Connecticut Could Permit Stronger Cannabis Products with High-Potency Label
Connecticut cannabis high-potency labeling is proposed to permit stronger THC products. This change impacts clinical counseling on potency-related risks. Clinicians must stay informed to advise patients safely.
Feds Maintain Marijuana Testing Despite Cannabis Reclassification
Federal workplace drug testing policies continue to screen for marijuana metabolites despite cannabis reclassification. This creates challenges for patients using cannabis medicinally in safety-sensitive jobs. Clinicians should counsel patients on the…
Using Medical or Recreational Marijuana to Ease Symptoms of Numerous Mental Health Conditions
Cannabis mental health symptoms management is increasingly relevant as patients self-medicate with CBD and THC products. Clinical evidence remains limited and mixed, requiring careful evaluation. Understanding cannabis mental health symptoms helps…